miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 15, 2026

Wells Fargo Gets Three Price Target Cuts in One Day: Is the ROTCE Recovery Story Falling Apart?

View original at finance.yahoo.com
Wells Fargo Gets Three Price Target Cuts in One Day: Is the ROTCE Recovery Story Falling Apart? Quick Read Wells Fargo (WFC) got hit with price target cuts from Barclays, Bank of America, and Piper Sandler following Q1 earnings, with BofA making the sharpest reduction to $95 from $107…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo asset quality remained stable and buybacks continued

    60% confidence

  • Wells Fargo's net interest margin contraction of 13 basis points quarter-over-quarter is the real sticker shock

    60% confidence

  • The path to 17% to 18% ROTCE is narrowing for Wells Fargo

    60% confidence

  • Wells Fargo earnings excluding tax benefit were light, with net interest income, fees, and expenses all coming in below expectations

    60% confidence

  • Net interest margin contraction raises further doubts around the ROTCE improvement thesis

    60% confidence

Data points we hold from this source

Wells Fargo & Company · eps estimate fy20266.72 USD
Wells Fargo & Company · eps estimate fy20277.36 USD
Wells Fargo & Company · price target108 USD
Wells Fargo & Company · ytd stock performance-13 percent
Wells Fargo & Company · net interest margin change-13 basis_points
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Wells Fargo Gets Three Price Target Cuts in One Day: Is the ROTCE Recovery Story Falling Apart? — Source | Via News | es.VIA.NEWS